Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines

Sakamoto, Tomoyuki; Tanaka, Yasuhito; Orito, Etsuro; Co, Jonard; Clavio, Joseph; Sugauchi, Fuminaka; Ito, Kiyoaki; Ozasa, Atsushi; Quino, Alvin; Ueda, Ryuzo; Sollano, José D.; Mizokami, Masashi

doi:10.1099/vir.0.81714-0

Cited by 106 publications

(103 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the Philippines, a cross-sectional study of 100 HBV carriers with various stages of liver disease revealed that 51 HBV genotype A1, 22 genotype B and 27 genotype C strains, and genotypes B and C were more prevalent than genotype A in cirrhosis and HCC patients (P \ 0.02). In addition, the prevalence of BCP T1762/A1764 mutant was higher in HCC patients with genotypes B and C. Multivariate analysis indicated that age and core promoter mutation were risk factors for HCC development [83]. Taking these lines of evidence together, BCP T1762/A1764 mutation seems to play an important role in the pathogenesis of liver disease progression and serve as the strongest viral factor associated with HCC risk in HBV carriers.…”

Section: Naturally Occurring Mutantsmentioning

confidence: 90%

Role of viral factors in the natural course and therapy of chronic hepatitis B

Kao

2007

Hepatol Int

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global health problem that causes a wide spectrum of liver disease, including acute or fulminant hepatitis, inactive carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The pathogenesis of hepatocyte damage associated with HBV is mainly through immune-mediated mechanisms. On the basis of the virus and host interactions, the natural history of HBV carriers who are infected in early life can be divided into four dynamic phases. The frequency, extent, and severity of hepatitis flares or acute exacerbation in the second immune clearance and/or fourth reactivation phase predict liver disease progression in HBV carriers. In the past decade, hepatitis B viral factors including serum HBV DNA level, genotype, and naturally occurring mutants predictive of clinical outcomes have been identified. The higher the serum HBV DNA level after the immune clearance phase, the higher the incidence of adverse outcomes over time. In addition, high viral load, genotype C, basal core promoter mutation, and pre-S deletion correlate with increased risk of cirrhosis and HCC development. As to the treatment of chronic hepatitis B, patients with high HBV DNA level and genotype C or D infection are shown to have a worse response to interferon therapy. In conclusion, serum HBV DNA level, genotype, and naturally occurring mutants are identified to influence liver disease progression and therapy of chronic hepatitis B. More investigations are needed to clarify the molecular mechanisms of the viral factors involved in the pathogenesis of each stage of liver disease and the response to antiviral treatments.

show abstract

Section: Naturally Occurring Mutantsmentioning

confidence: 90%

Role of viral factors in the natural course and therapy of chronic hepatitis B

Kao

2007

Hepatol Int

View full text Add to dashboard Cite

show abstract

“…Base on the inclusion criteria, only 17 case-control studies (Sakamoto et al, 2006;Tanaka et al, 2006;Shinkai et al, 2007;Wang et al, 2007;Yuan et al, 2007;Zhang et al, 2007;Fang et al, 2008;Guo et al, 2008;Jang et al, 2008;Choi et al, 2009;Ja et al, 2009;Tangkijvanich et al, 2010;Welschinger et al, 2010;Zhu et al, 2010;Cho et al, 2011;Qu et al, 2011;Tatsukawa et al, 2011) with full-text were included in this meta-analysis and 18 studies were excluded. The flow chart of study selection is summarized in Figure 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

Hepatitis B Virus Gene C1653T Polymorphism Mutation and Hepatocellular Carcinoma Risk: an Updated Meta-analysis

Shi¹,

Zhang²,

Shang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Although there have been many studies investigating possible associations between the C1653T mutation and risk of HCC, the results have been inconsistent. We conducted searches of the published literature in Pubmed and Embase databases up to January 2013. Seventeen studies with a total of 1,085 HCC cases and 1,365 healthy controls were retrieved.We found a significant association between the C1653T mutation and HCC risk (OR = 2.01, 95%CI= 1.49-2.70). In the subgroup analysis by ethnicity, a significant association was also found in Asians (OR = 2.07, 95%CI= 1.71-2.51). In subgroup analysis by HBV genotype, B and C were linked with development of HCC (B:OR = 2.21, 95%CI= 1.13-4.34; C:OR = 2.26, 95%CI= 1.61-3.16). However, no significant association was found between the C1653T mutation and HCC risk in HBeAg positive cases. In conclusion, this meta-analysis suggests that the C1653T mutation may be associated with susceptibility to HCC.

show abstract

“…Recently, two novel genotypes, I and J, the former described in Laos and Vietnam (Olinger et al, 2008;Tran et al, 2008), and the latter in Japan (Tatematsu et al, 2009), have been proposed, but their designation as new genotypes is still controversial. There is a great deal of diversity within the genotypes and this has led to the division of some genotypes into different subgenotypes, such as A1-A6 in HBV of genotype A (HBV/A), B1-B8 in HBV/B, C1-C10 in HBV/C, D1-D7 in HBV/D, and F1-F4 in HBV/F (Huy et al, 2006;Kramvis et al, 2008;Lusida et al, 2008;Meldal et al, 2009;Mulyanto et al, 2009;Norder et al, 2004;Nurainy et al, 2008;Pourkarim et al, 2010;Sakamoto et al, 2006;Utsumi et al, 2009;Wang et al, 2007). …”

Section: Geographic Distribution Of Hbv Genotypes In the General Popumentioning

confidence: 99%